08-11-2012 дата публикации
Номер: US20120283272A1
The invention relates to certain compounds, or pharmaceutically acceptable salts, solvates, clathrates, or prodrugs thereof, that are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders. 2. The compound of claim 1 , wherein Z is (C-C)alkyl claim 1 , (C-C)alkenyl claim 1 , (C-C)alkynyl claim 1 , heteroaryl claim 1 , CO claim 1 , COO claim 1 , CON(R) claim 1 , CS claim 1 , CSO claim 1 , or CSN(R).3. (canceled)4. The compound of claim 1 , wherein Z is a bond.5. The compound of claim 1 , wherein Ris heteroaryl.6. The compound of claim 5 , wherein Ris pyridinyl claim 5 , pyrazolyl claim 5 , oxazolyl claim 5 , imidazolyl claim 5 , or tetrazolyl claim 5 , each of which may be N-substituted with (C-C)alkyl claim 5 , which may in turn be substituted with N(R).7. The compound of claim 1 , wherein Ris (C-C)alkyl claim 1 , (C-C)alkenyl claim 1 , or heteroaryl claim 1 , each of which is optionally substituted with one to three halo claim 1 , (C-C)alkyl claim 1 , (C-C)alkenyl claim 1 , (C-C)alkynyl claim 1 , COR claim 1 , COOR claim 1 , CON(R) claim 1 , N(R) claim 1 , NRCON(R) claim 1 , NRCSN(R) claim 1 , OR claim 1 , SR claim 1 , CN claim 1 , NO claim 1 , or N.8. The compound of claim 1 , wherein Rand Rare H.9. The compound of claim 1 , wherein n is 2 claim 1 , and Ris halo.1011-. (canceled)12. The compound of claim 1 , wherein Xis C claim 1 , and Xis N.13. The compound of claim 1 , wherein Xis N claim 1 , and Xis C.14. The compound of claim 1 , wherein Yis S claim 1 , and Yis CH.15. The compound of claim 1 , wherein Yis S claim 1 , and Yis N.16. The compound of claim 1 , wherein Yis S.17. (canceled)19. (canceled)20. A pharmaceutical composition claim 1 , comprising a pharmaceutically acceptable carrier and a compound of claim l.2129-. (canceled) This application claims the benefit of U.S. Provisional Application No. 61/194,831, filed Oct. 1, 2008, the entire disclosure of which is incorporated ...
Подробнее